US generic drugmaker Impax Laboratories conducts strategic review

08 Mar 2017

1

US generic and specialty pharmaceutical company Impax Laboratories Inc is conducting a strategic review which includes an acquisition or a sale of the company, Reuters today reported, citing people familiar with the matter.

The Pennsylvania-based company has hired investment bank Morgan Stanley to help it conduct a strategic review, as it tries to cope with a tougher drug pricing environment, the report said.

Impax shares rose by as much as 11 per cent on the news, and were trading at $8.70 on the Nasdaq in afternoon on Tuesday, giving the company a market cap of around $700 million.

Impax is focused on the development and commercialisation of bioequivalent and brand-name pharmaceuticals as well as selling generic drugs.

In the generic pharmaceuticals market, the company focuses on controlled-release generic versions of brand-name pharmaceuticals, covering a range of therapeutic areas. In the brand-name pharmaceuticals market, the company is developing products for the treatment of central nervous system disorders.

It employs over 1,000 people, has manufacturing plants in Hayward, California; Middlesex, New Jersey; and Taiwan, and has annual revenues of around $825 million.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more